The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
.png)
4990 Ash Street, Dallas, Texas 75207 972-815-7120
972-815-7120
admin@finhub.com
Copyright © 2024 finance. All Rights Reserved
